High-throughput NGS solutions for reliable detection of emerging SARS-CoV-2 variants
The emergence of new SARS-CoV-2 variants such as B.1.1.7 and B.1.351 is changing the trajectory of the pandemic. Cataloging these variants and evaluating the impact of mutations is critical for effective vaccine development and the implementation of a robust public health response. Partner with QIAGEN to expedite SARS-CoV-2 variant detection and phylogeographic tracking using reliable, high-throughput NGS technologies and integrated bioinformatics pipelines. From genomic surveillance to metatranscriptomics – uncover the multiple facets of SARS-CoV-2 biology with precision.
Coronavirus research publications using QIAGEN technologies
- QIAseq technology shown to be among the most effective for SARS-CoV-2 whole genome sequencing
A recent study evaluating different SARS-CoV-2 whole genome sequencing methods revealed that the QIAseq SARS-CoV-2 Primer Panel enabled preferential amplification of the SARS-CoV-2 genome by up to 100-fold and ensured high coverage.
Reference: Liu et al. (2020) A benchmarking study of SARS-CoV-2 whole-genome sequencing protocols using COVID-19 patient samples
- Uncovering the SARS-CoV-2 mutational landscape with QIAseq technology
Explore how combining QIAseq FastSelect and QIAseq FX technologies to generate NGS libraries free from human rRNA facilitated deeper insights in this SARS-CoV-2 phylogenetics study.
Reference: Hartley et al. (2020) Genomic surveillance of Nevada patients revealed prevalence of unique SARS-CoV-2 variants bearing mutations in the RdRp gene
- Is reinfection with SARS-CoV-2 possible?
Explore how this study used QIAseq FastSelect for rRNA removal and QIAseq FX for viral genome amplification and sequencing to uncover genetic discordance between SARS-CoV-2 isolates.
Reference: Tillett et al. (2020) Genomic evidence for a case of reinfection with SARS-CoV-2
- Tracking mutations in SARS-CoV-2 RNA using QIAseq technology
Discover how the QIAseq SARS-CoV-2 Primer Panel helped reveal a bird’s eye view on the accumulation of mutations in the SARS-CoV-2 genome in this study from Eastern India.
Reference: Maitra, A. et al. (2020) Mutations in SARS-CoV-2 viral RNA identified in Eastern India: Possible implications for the ongoing outbreak in India and impact on viral structure and host susceptibility
- The crucial role of QIAseq FX technology in SARS-CoV-2 sequencing
This publication by Itokawa et al. cites the use of QIAGEN’s QIAseq FX technology for converting amplicons into high-quality NGS-ready libraries ready for sequencing.
Reference: Itokawa, K., Sekizuka, T., Hashino, M., Tanaka, R., and Kuroda, M. (2020) Disentangling primer interactions improves SARS-CoV-2 genome sequencing by the ARTIC Network’s multiplex PCR
- High-quality library prep for SARS-CoV-2 sequencing using QIAseq FX
This study by Itokawa et al. illustrates the use of QIAGEN’s QIAseq FX technology for high-quality library prep for sequencing the SARS-CoV-2 genome.
Reference: Itokawa, K., Sekizuka, T., Hashino, M., Tanaka, R., and Kuroda, M. (2020) A proposal of an alternative primer for the ARTIC Network’s multiplex PCR to improve coverage of SARS-CoV-2 genome sequencing
Enabling high-throughput genomic surveillance of emerging SARS-CoV-2 strains B.1.1.7 and B.1.351Speakers: Brian Dugan, M.S., Associate Director, Global Product Management, Genomics, QIAGEN and Shawn Prince, B.S., Senior Field Application Scientist, Bioinformatics, QIAGEN
rRNA removal for RNA-seq applications involving viruses, host responses and metatranscriptomicsSpeaker: Samuel Rulli, Ph.D., Associate Director, RNA-seq profiling, NGS assay technologies, QIAGEN
On-demand recorded webinar
Targeted RNA panels to identify SARS-CoV-2 and study host gene expressionSpeaker: Samuel Rulli, Ph.D., Associate Director, RNA-seq profiling, NGS assay technologies, QIAGEN
On-demand recorded webinar